Brief: Celyad Announces Q1 2019 Financial Results And Recent Business Highlights

Celyad Oncology SA

09/05/2019 06:28

May 9 (Reuters) - CELYAD SA  CYAD.BR :
    * CELYAD ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS AND
RECENT
BUSINESS HIGHLIGHTS
    * CLINICAL UPDATES FROM PHASE 1 THINK AND DEPLETHINK TRIALS
ARE
ANTICIPATED BY MID-2019
    * COMPANY ENDED Q1 WITH EUR 40.5 MILLION ($45.4 MILLION) IN
CASH,
CASH EQUIVALENTS AND SHORT-TERM BANK DEPOSITS
    * FOR FY 2019 SEES ADVANCEMENT TOWARDS AN IND APPLICATION
WITH
PRECLINICAL DEVELOPMENT OF NEXT-GENERATION NKG2D-BASED CAR-T,
CYAD-02
    * NET CASH BURN OVER Q1 OF 2019 AMOUNTED TO EUR 8.6 MILLION,
IN
LINE WITH EXPECTATIONS
    * CONFIRMS ITS PREVIOUS GUIDANCE THAT ITS TREASURY POSITION
SHOULD
BE SUFFICIENT TO FUND OPERATING EXPENSES AND CAPITAL EXPENDITURE
REQUIREMENTS, BASED ON CURRENT SCOPE OF ACTIVITIES, UNTIL
MID-2020
    * FOR FY 2019 SEES FURTHER PURSUE DEVELOPMENT OF PROPRIETARY
NON-GENE EDITED ALLOGENEIC SHRNA PLATFORM AND PROGRESS TOWARDS
IND APPLICATIONS FOR CYAD-200 SERIES OF SHRNA-BASED CAR-T
CANDIDATES

Source text for Eikon:  ID:nGNX35RdKv 
Further company coverage:  CYAD.BR 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))